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 An LC-MS/MS method quantifying 4 vitamin D metabolites using LLE was developed 
 Quality controls made from pooled, unspiked sera led to improved accuracy  
 Method applied to the re-analysis of 159 biobanked sera 
 Accurate metabolite measurements were used to explain immunoassay cross-reactivity 
 
ABSTRACT 
Measurement of serum 25-hydroxyvitamin D [25(OH)D] is considered the best indicator of 
vitamin D status. Two minor vitamin D metabolites are common interferences encountered in 
25(OH)D assays. The first is 3-epi-25-hydroxyvitamin D3 [3-epi-25(OH)D3], which if not 
chromatographically resolved from 25-hydroxyvitamin D3 [25(OH)D3], can overestimate 
25(OH)D concentrations. The second is 24R,25-dihydroxyvitamin D3 [24R,25(OH)2D3], which 
can cross-react with the antibodies in 25(OH)D immunoassays. Our aim was to develop an LC-
MS/MS method capable of detecting both 3-epi-25(OH)D3 and 24R,25(OH)2D3 in serum without 
the use of a derivatization agent. We report an isotope dilution LC-MS/MS method, with 
electrospray ionization in the positive mode, that can simultaneously detect 24R,25(OH)2D3, 
25(OH)D3, 3-epi-25(OH)D3, and 25-hydroxyvitamin D2. The method employs a cost-effective 
liquid-liquid extraction using only 150 µL of sera and a total run time of 10 minutes. Method 
performance was assessed by using quality controls made from pooled sera as an alternative to 
sera spiked with analytes.  Biobanked samples, originally analyzed by chemiluminescent 
microparticle immunoassay (CMIA), were re-analyzed with this method to determine the 
contribution of 24R,25(OH)2D3 cross-reactivity to 25(OH)D measurement bias. The CMIA over-
estimation of 25(OH)D measurements relative to LC-MS/MS was found to depend on both 








Vitamin D is unique in that it is both produced endogenously through the action of sunlight 
on the skin, and obtained through the diet. The primary endogenous form of the vitamin 
produced in the skin and supplied in the diet is vitamin D3 (cholecalciferol), while vitamin D2 
(ergocalciferol) is a minor dietary-derived form. Each of these vitamers is hydroxylated in the 
liver to 25-hydroxyvitamin D3 [25(OH)D3] and 25-hydroxyvitamin D2 [25(OH)D2], respectively 
(Figure 1), and are then bound to the vitamin D binding protein and circulate in the blood. The 
sum of these two metabolites in the circulation is referred to as total 25-hydroxyvitamin D 
[25(OH)D], which is currently regarded as the best indicator of vitamin D status [1]. Efforts to 
standardize 25(OH)D measurement across multiple analytical platforms continue through 
certification and/or accuracy-based quality assurance programs, such as the Vitamin D 
Standardization Certification Program (VDSCP), operated by the Centers for Disease Control 
and Prevention, and the Vitamin D External Quality Assessment Scheme (DEQAS) at Charing 
Cross Hospital, London [2]. Tandem liquid chromatography-mass spectrometry (LC-MS/MS) 
has emerged as the preferred analytical technique used for reference measurement procedures 
[3-6], but immunoassays are widely employed in clinical settings [7]. 
 Two other minor circulating vitamin D metabolites are known to interfere with 25(OH)D 
assays. An epimer of 25(OH)D3 [3-epi-25(OH)D3] (Figure 1) is present in the circulation, and if 
not chromatographically resolved from 25(OH)D3, may contribute to an over-estimation of total 
25(OH)D, particularly in pediatric populations in which the relative concentration of 3-epi-
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25(OH)D3 is greater than those of adults [8, 9]. The first metabolite in the catabolic pathway of 
25(OH)D3 is 24R,25-dihydroxyvitamin D3 [24R,25(OH)2D3] (Figure 1). As 25(OH)D3 
concentration in serum increases, both24R,25(OH)2D3 and 3-epi-25(OH)D3 concentrations 
increase likewise [7, 8]. The ratio of 24R,25(OH)2D3 to 25(OH)D3 has been suggested in recent 
times as an additional marker of vitamin D status [10-12]. However, 24R,25(OH)2D3 is also 
known to interfere with 25(OH)D immunoassays [7]. Through the work of DEQAS, Carter et al. 
[13] have shown that the cross-reactivity of common ligand binding assays to spiked 
24R,25(OH)2D3 varied from <5% to 548%, but that the calculated cross-reactivity from spiked 
samples did not accurately predict the cross-reactivity of endogenous 24R,25(OH)2D3 in native 
samples. This effect of 24R,25(OH)2D3 on the assessment of total 25(OH)D may explain, at 
least in part, the recent findings by Cashman et al. [14, 15] that have shown a number of 
immunoassays over-estimate serum 25(OH)D concentrations relative to LC-MS/MS, especially 
when total 25(OH)D concentrations exceeds 50-80 nmol/L.  
There are relatively few LC-MS/MS methods in the literature that quantify both 
24R,25(OH)2D3 and 3-epi-25(OH)D3. A common strategy is derivatization of the cis-diene 
moiety of vitamin D metabolites with Cookson-type reagents [16-18] to increase sensitivity by 
improving ionization. Müller et al. [19], Satoh et al. [20] and Hanson et al. [21] have followed this 
approach using proprietary Ampliflex® [22] or custom-synthesized DAPTAD (4-(4'-
dimethylaminophenyl)-1,2,4-triazoline-3,5-dione) and DMEQ-TAD (4-[2-(6,7-dimethoxy-4-
methyl-3-oxo-3,4-dihydroquinoxalyl)ethyl]-1,2,4-triazoline-3,5-dione) as the dienophiles, 
respectively. Non-derivatized methods for vitamin D metabolites that included both 
24R,25(OH)2D3 and 3-epi-25(OH)D3 have been reported using two-dimensional 
chromatography by Mena-Bravo et al. [23], Baecher et al. [24], and Clarke et al. [25]. Jenkinson 
et al. [26] have reported an underivatized method using online solid phase extraction (SPE) that 
analyzes 10 vitamin D metabolites in 8 min, including 24R,25(OH)2D3 and 3-epi-25(OH)D3. 
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Specialist chemical reagents, two-dimensional chromatography, or on-line SPE may not be 
practical options for many laboratories. In recent times, we developed a LC-MS/MS method 
capable of measuring 25(OH)D2, 25(OH)D3 and its epimer that employed a simple, inexpensive 
liquid-liquid extraction (LLE), without derivatization, that required minimal training to perform 
[27]. Our aim in the present work was to incorporate the 24R,25(OH)2D3 analyte into this 
existing LC-MS/MS method. The type of quality control sample employed proved to be essential 
for optimal method development. Finally, by accurately quantifying the serum 24R,25(OH)2D3 
using this new LC-MS/MS method, we aimed to illustrate how naturally present 24R,25(OH)2D3, 
via cross-reactivity with antibody in a representative immunoassay, led to inflated estimates of 
total 25(OH)D.  
 
2. Materials and methods 
2.1. Chemical reagents, standards, and columns 
All reagents were LC-MS grade unless indicated otherwise. Hexane (HPLC grade), ethanol 
(HPLC grade), methanol, formic acid, ammonium acetate, and zinc sulfate heptahydrate 
(reagent grade) were purchased from Sigma-Aldrich (Wicklow, Ireland).  Isotopically labelled 
[13C]3-25(OH)D2 (50 µg/mL), d6-25(OH)D3 (100 µg/mL), d3-3-epi-25(OH)D3 (100 µg/mL), d6-
24R,25(OH)D3 (100 µg/mL), and unlabelled 24R,25(OH)D3 (100 µg/mL) were purchased 
from Isosciences as solutions in ethanol (Trevose, PA, USA). The purity of the 
24R,25(OH)D3 standard solution was 97%, as determined by HPLC with PDA detector set to 
265 nm. A stock solution of 24R,25(OH)D3 was prepared from the purchased solution by 
dilution with ethanol to a concentration of 231.8 nmol/L (adjusted for purity).  Certified 
calibrators SRM 2972a for 25(OH)D2, 25(OH)D3 (2 levels), 3-epi-25(OH)D3 were purchased 
from the National Institute of Standards and Technology (NIST) (Gaithersburg, MD, USA). 
All of the above standards and stock solutions were stored at -20⁰ C.  Internal standard 
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blanks were run daily, and isotope composition remained stable for up to one year.  The 
chromatographic column, Supelco Ascentis® Express F5 100mm x 2.1mm, 2.7μm and 
guard columns 5mm X 2.1mm, 2.7μm, 3-pk were available from Sigma-Aldrich. 
2.2. Preparation of Quality Control material 
Standard Reference Materials (SRM) 972a - Vitamin D Metabolites in Human Frozen Serum 
was obtained from NIST. In-house QC sera (Pooled Control I, II and III) were created from 
pooled sera to represent 3 clinically relevant concentration ranges of 25(OH)D: <30 nmol/L 
that represents increased risk of vitamin D deficiency [28], >50 nmol/L representing vitamin 
D adequacy [28], and >75 nmol/L suggested by some to maximize the effect of vitamin D on 
calcium, bone, and muscle metabolism [29]. Spiked Control A was prepared by spiking 
Pooled Control I with 25.0 nmol/L of 24R,25(OH)2D3. Bi-level QCs based on lyophilized 
human serum and enhanced with 3-epi-25(OH)D3/D2 and/or 25(OH)D2 were purchased from 
Chromsystems (Gräfelfing, Germany); these will be referred to as Spiked Controls B-E.  
2.3. Calibration curve 
All internal standard (IS) and calibration solutions were prepared daily. Sufficient volume of 
IS was prepared for addition to the standard curve and to serum samples. The IS spiking 
solution was prepared from stock solutions to concentrations of 250 ng/mL d6-25(OH)D3, 
125 ng/mL [13C]3-25(OH)D2, and 62.5 ng/mL of d3-3-epi-25(OH)D3 and d6-24R,25(OH)D3 in 
ethanol. A 100 µL aliquot of IS solution was evaporated under nitrogen at room temperature 
and re-constituted in 1000 µL 32:68 water:methanol for use as the diluent for the preparation 
of the calibrators. To prepare the highest calibrator, aliquots of NIST 2972a solutions 
25(OH)D3 (Level 1), 25(OH)D2, 3-epi-25(OH)D3 and 24R,25(OH)D3 stock solution were 
evaporated under nitrogen at room temperature and re-constituted in 200 µL IS diluent to 
give concentrations of 323, 140, 86.6, 73.4 nmol/L of 25(OH)D3, 25(OH)D2, 3-epi-25(OH)D3 
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and 24R,25(OH)2D3, respectively. This standard was serially diluted with IS diluent to 
produce a 7 point calibration curve.  
2.4.  Sample extraction 
To 150 μL serum aliquots, 15 μL of IS solution was added and allowed to stand at room 
temperature for approximately 15-30 minutes.  Vitamin D metabolites were unbound from 
the vitamin D binding protein and proteins were precipitated with the sequential addition of 
150 μL 0.2M aqueous zinc sulfate solution and 300 μL methanol, vortexing after each 
addition. LLE was performed using 750 µL 30% ethyl acetate in hexane by vortex mixing for 
2 minutes and centrifugation for 5 minutes to remove solids. The organic extract was 
transferred to high recovery HPLC vials and evaporated in a vacuum centrifuge at 30°C, 
then reconstituted in 100 µL 32:68 water:methanol for injection into the LC-MS/MS. 
2.5. LC-MS/MS analysis 
Analysis was performed on a Waters Acquity UPLC™ with triple quadrupole mass detector 
(TQD) using electrospray ionization (ESI) in the positive mode. The column oven 
temperature was set to 35°C, while the samples were maintained at 10°C. Mobile phase A 
was 0.1% formic acid, 2 mM ammonium acetate in water, mobile phase B was 0.1% formic 
acid, 2 mM ammonium acetate in methanol, and the flow rate was 0.45 mL/min. The sample 
was injected using full loop mode with a 20 µL loop and overfill factor of 3. The initial mobile 
phase composition was 35% A, 65% B and was maintained for 4.5 min; a non-linear 
gradient started at 4.5 min and ended at 28% A, 72% B after 8 min; high organic phase 2% 
A, 98% B flushed the column from 8 to 9.5 min; finally, initial conditions were restored for a 
total run time of 10 min. The conditions for the Waters Acquity TQD are listed in Table 1. A 




Statistical analysis was performed with SPSS® Statistics Version 22.0.0.1 (IBM®, USA). 
Graphical plots were created using SPSS® and Excel® 2013 (15.0.4569.1504; Microsoft®, 
USA). 
 
3. Method Development 
3.1. Improving accuracy of 24R,25(OH)2D3 measurement 
Guidelines from the European Medicines Agency (EMA) and the Food and Drug 
Administration (FDA) [30, 31] state that QCs for bio-analytical methods are created by 
spiking known amounts of analyte into blank biological matrix.  In the initial phase of method 
development and in accordance with these guidelines, blank serum samples, ie. serum 
samples that contained no detectable 24R,25(OH)2D3 were spiked with 10, 15 or 20 nmol/L 
24R,25(OH)2D3. However, sera that naturally contained >10 nmol/L 24R,25(OH)2D3 also 
contained a shoulder peak not present in spiked samples. 
To illustrate, Figure 2A shows the 417.3 > 121.0 MRM chromatogram of a sample 
measuring 117 nmol/L 25(OH)D3 and 15 nmol/L 24R,25(OH)D3 with a clearly visible 
shoulder peak. Figure 2B is a sample containing 16 nmol/L 25(OH)D3 that was spiked with 
15 nmol/L 24R,25(OH)D3 and does not have this interfering peak. The absence of this peak 
in the low 25(OH)D3 samples spiked with 24R,25(OH)2D3 underestimated the true bias of 
samples with high 25(OH)D3 and 24R,25(OH)2D3. A modified gradient method (as described 
in Section 2.5) was able to separate this peak, as shown in Figure 2C. The mean retention 
time difference between 24R,25(OH)2D3 and the unknown was 0.60 + 0.03 minutes (10 runs 
over two days). 
The area under the curve (AUC) of the unknown peak increased as the 25(OH)D3 
increased in the pooled controls (r=0.818, p <0.001). The mean AUC (n=9) of the unknown 
peak was 28.067, 64.256, and 89.033 for QC I, II, and III, respectively. Comparison of 
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retention times of known isobaric interferences 23,25(OH)2D3 and 3-epi-24,25(OH)2D [3] 
eliminated these compounds as the possible identity of the unknown. The biologically active 
vitamin D metabolite 1,25(OH)2D3 is hydroxylated at carbon positions 1,3,25 and has a 
different fragmentation pattern [22] that is not detected in the 417.3 > 121.0 transition. 
Synthetic vitamin D analogues used to treat vitamin D related pathologies typically have 
hydroxyl groups at carbons 1 and 3 [32, 33] and likewise would not be observed in this 
transition.  
3.2. Accuracy and selectivity 
Pooled sera at three different concentration ranges of 25(OH)D3 (as outlined in Section 2.2) 
were used to assess method performance. Concentration values for 24R,25(OH)2D3, 
25(OH)D3, 25(OH)D2, 3-epi-25(OH)D3 were assigned by measuring each pooled control in 
duplicate in 3 separate assays. NIST SRM 972a, Level 1-4 was analyzed concurrently with 
these in-house control sera to verify the accuracy of the measurements.  Vitamin D 
metabolite target values assigned by NIST are provided in Table 2 [34], and the analyte 
ranges of these reference sera are similar to those of the pooled controls and individual 
samples, with the exception of Level 4 which is artificially enhanced with 3-epi-25(OH)D3.  
The mean bias of each analyte relative to NIST target values was 12.0%, -1.5%, -1.7%, and 
-4.9% for 24R,25(OH)2D3, 25(OH)D3, 25(OH)D2, and 3-epi-25(OH)D3, respectively. Specific 
details of the SRM 972a analysis are discussed elsewhere [35].   
Figure 3 shows the overlaid MRM chromatograms of the four vitamin D metabolite 
standards. Because they have the same mass transitions, 25(OH)D3 and 3-epi-25(OH)D3 
peaks are in the same MRM chromatogram, shown in grey. Baseline separation between 
25(OH)D3 and 3-epi-25(OH)D3 had been achieved, and while 3-epi-25(OH)D3 and 25(OH)D2 
co-eluted, they were different masses and could be analyzed concurrently. No cross-talk 
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was observed between 3-epi-25(OH)D3 and 25(OH)D2 or their isotopically labelled 
standards. 
3.3. Linearity and linear range, sensitivity, stability 
The performance characteristics of the LC-MS/MS assay are shown in Table 3. The linear 
ranges correspond to the lower and upper limits of quantitation (LLOQ and ULOQ, 
respectively). The limits of detection (LOD) were the concentrations at which the signal-to-
noise (S/N) ratio of the analyte in serum matrix was no less than 3.  The LLOQ was 
determined by the analyte concentration at which the RSD was 20%. The r2 values for all 
calibration curves were >0.995.  The linear range for 24R,25(OH)2D3 was demonstrated by 
spiking QC samples with 25 nmol/L (~50% ULOQ) and 55 nmol/L (~75% ULOQ) in 
duplicate, and spike recovery ranged from 92-109%. Linear ranges of the other 3 analytes 
had already been established [27]. To test for stability of the analytes, sera were subjected 
to 3 freeze-thaw cycles or were left at ambient temperature (20-25°C) under amber light for 
4 days. No statistically significant differences were seen in the analytes prior to and following 
the test conditions (data not shown). 
3.4. Precision and recovery 
Intra-assay precision was determined by 5 replicates of Pooled Controls I-III within a single 
assay; inter-assay precision was determined by taking duplicate measurements and 
comparing over three days. The RSD for each analyte is shown in Table 3. The mean intra- 
and inter-assay RSD was less than 15% for all analytes within the limits of quantitation, 
fulfilling method validation guidelines [30, 31]. Post-extraction recoveries of 8 individual sera 
are provided in Table 3.  The lower recovery of 24R,25(OH)2D3 is due to loss to the aqueous 
layer on account of its higher polarity, not due to ion suppression of the matrix (which was 
determined by comparison of IS recovery from extracted serum matrix to IS recovery from 
extracted phosphate buffered saline blank matrix). 
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3.5. Measurement of sera from the Finnish Migrant Health and Wellbeing Study 
The Finnish Migrant Health and Wellbeing Study (referred to as Maamu), a representative 
sample of 1,310 immigrants that were Russian-speaking or of Somali or Kurdish origin and 
living in 6 cities in Finland [36], originally assessed serum total 25(OH)D by an Architect 
Chemiluminescent Microparticle Immuno-Assay (CMIA). As part of a pan-European study, 
several representative samples, including Maamu, were standardized in terms of their 
25(OH)D data [15]. This entailed a subset (n=159) of the entire Maamu collection of bio-
banked sera being re-analyzed by our original LC-MS/MS method (that did not include 
24R,25(OH)2D3), as described in detail elsewhere [15]. This exercise showed that total 
25(OH)D concentrations as measured by CMIA were positively biased compared to that 
derived by our LC-MS/MS analysis, especially evident at 25(OH)D concentrations above 
~80 nmol/L. In the present work, biobanked serum samples with sufficient volume remaining 
(n=156) were again re-analyzed but with our new LC-MS/MS method that included 
measurement of 24R,25(OH)2D3.  
 
4. Results and Discussion 
In Sections 2 and 3 above, we report a simple, cost-effective, accurate isotope dilution LC-
MS/MS method using LLE that is capable of simultaneously detecting 24R,25(OH)2D3, 
25(OH)D3, 3-epi-25(OH)D3, and 25(OH)D2 in only 150 µL serum without the use of a 
derivatization agent. We used the re-analyzed Maamu sample subset to test how well pooled 
controls I-III and spiked controls A-E (see Section 2.2) behaved in terms of relationships 
between 24R,25(OH)2D3 and 3-epi-25(OH)D3 and their parent metabolite 25(OH)D3 at different 
concentrations.  LC-MS/MS measured serum concentrations of 25(OH)D3, 25(OH)D2, 
24R,25(OH)2D3 and 3-epi-25(OH)D3 in the entire subset of Maamu sample as well as stratified 
according to low (<30 nmol/L), medium (30-75 nmol/L), and high (>75 nmol/L) 25(OH)D3 
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concentrations are shown in Table 4. Serum 24R,25(OH)2D3 and 3-epi-25(OH)D3, but not 
25(OH)D2, increase as the concentration of 25(OH)D3 increases. For four out of the five spiked 
controls, the relative concentrations of 25(OH)D3, 24R,25(OH)2D3 and 3-epi-25(OH)D3 fell 
outside the normal proportions observed for unaltered serum. When preparing spiked samples, 
each metabolite is elevated at concentrations independent of each other. When looking at 
metabolites within the same pathway, concentrations of each metabolite are not independent 
but depend on the concentration of the parent compound, in this case 25(OH)D3. By pooling 
serum at different concentrations of the parent 25(OH)D3, the vitamin D metabolites 
24R,25(OH)2D3 and 3-epi-25(OH)D3 maintained their relative proportions to 25(OH)D3 without 
the need for exogenous spiking.   
Thus, by using controls that reflect the relative proportions of both known vitamin D 
metabolites, but also possibly correlated unknowns, performance assessment of precision and 
accuracy would more realistically reflect what is observed in real samples. As can be seen in 
Table 3, analyte precision is not constant at different concentrations. If, for example, the 
precision of 25(OH)D2 measurement was determined using spiked controls B-E with ~40 or ~85 
nmol/L 25(OH)D2, as shown in Table 4, precision may be estimated to be better than what 
would be expected from typical samples with a concentration range of 1-16 nmol/L. For the 
assessment of accuracy, serum spiked with 24R,25(OH)2D3 did not contain an interfering 
compound present in serum with high 25(OH)D3 concentrations and gave misleading results 
(see Section 3.1). As an alternative to using spiked controls to assess accuracy, we analyzed 
four levels of NIST SRM 972a, which were also based primarily on unspiked pooled samples 
(except Level 4, which was spiked with 3-epi-25(OH)D3). Concentration values assigned by 
NIST for these four vitamin D metabolites were traceable to reference measurement procedures 




With confidence in our new method performance, we endeavored to determine if cross-
reactivity to increased levels of 24R,25(OH)2D3 was the primary cause of the positive bias of 
total 25(OH)D derived by CMIA relative to that from LC-MS/MS measurements within the 
Maamu sera. The best fit statistical model for predicting total 25(OH)D measured by LC-MS/MS 
from the total 25(OH)D measured by CMIA by accounting for the concentration of 
24R,25(OH)2D3 was: 
 [Total 25(OH)D by LC-MS/MS] = [Total 25(OH)D by CMIA] + 2.673 * [24R,25(OH)2D3] – 
0.034*[Total 25(OH)D by CMIA] * [24R,25(OH)2D3] - 3.859; R2 = 0.784.  
The CMIA -derived total 25(OH)D results were adjusted using this equation, and both 
adjusted and unadjusted CMIA results relative to LC-MS/MS estimates are plotted in Figure 4. 
The adjusted model predicted total 25(OH)D with closer agreement to LC-MS/MS estimates (R2 
= 0.941) than did the unadjusted CMIA measurements. According to Carter et al. [13], the 
Architect assay for total 25(OH)D had a cross-reactivity factor with 24R,25(OH)2D3 of 548%, 
calculated from the response to exogenously spiked 24R,25(OH)2D3. Consequently, the 
calculated over-reactivity was not able to accurately predict the measured CMIA total 25(OH)D. 
Our model predicted that for DEQAS sample 470 (118 nmol/L total 25(OH)D and 11 nmol/L 
24R,25(OH)2D3 as measured by the NIST Reference Measurement Procedure [12]), the 
Architect CMIA would have a measured value of total 25(OH)D=142 nmol/L. The actual value 
measured by the CMIA was 146 nmol/L, as reported by Carter et al. [13], highlighting how 
24R,25(OH)2D3 present in the serum may affect some immunoassay measurements of total 
25(OH)D and can lead to dramatically over-inflated estimates of serum total 25(OH)D, 
particularly in those samples with high serum 25(OH)D3 and thus high 24R,25(OH)2D3 
concentrations.  The present findings also support earlier suggestions that immunoassays may 
not react to 24R,25(OH)2D3-spiked samples in the same way as that in native, unspiked 
samples [10, 13]. 
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We had previously shown that the positive bias of the CMIA-derived estimate for serum 
total 25(OH)D within Maamu, compared to the LC-MS/MS estimates, became exaggerated at 
concentrations of 25(OH)D greater than ~90 nmol/L (i.e. the point at which the slope of relation 
between original CMIA and re-analyzed LC-MS/MS measured values changed; a slope of 1.02 
in the original CMIA concentration range of 0-80 nmol/L, and a slope of 0.34 in the 
concentration range of 90-180 nmol/L [15]).  Thus, importantly from a clinical perspective in 
terms of diagnosis of vitamin D deficiency and insufficiency, below serum total 25(OH)D 
concentrations of ~90 nmol/L the CMIA and LC-MS/MS analysis yielded relatively comparable 
estimates; however, above 90 nmol/L there was significant deviation in the estimates. While in 
this work a relatively small proportion (<5%) of subjects had serum concentrations above 90 
nmol/L as measured by CMIA, it is worth noting that the concentration at which this change 
point occurs can vary by immunoassay, and has been as low as 49 nmol/L [15].  From a public 
health perspective, the inflation of some immunoassay derived serum total 25(OH)D estimates, 
as a consequence of cross-reactivity with 24R,25(OH)2D3, can over-estimate the prevalence of 
serum 25(OH)D concentrations >125 nmol/L, which are regarded by the IOM committee as 
being of some reason for concern [28]. Selection of this threshold is based on reported U and 
reverse J-shaped associations between serum 25(OH)D and adverse consequences, including 
all-cause mortality, cancer, cardiovascular disease, parathyroid hormone suppression, and 
intrauterine growth restriction, among others [28,37,38].   
 
5. Conclusion 
We have developed a simple, cost-effective LC-MS/MS method using LLE that is capable of 
simultaneously detecting four vitamin D metabolites in only 150 µL serum. Pooled, unspiked 
serum used as QC samples more closely reflected the natural proportions of vitamin D 
metabolites when compared to control serum spiked with analytes, leading to a more accurate 
15 
 
assay. The application of pooled, unspiked QCs could be extended to other metabolic 
pathways, where relative proportions of each metabolite are under investigation.  Quantifying 
the vitamin D metabolites in relation to each other was important for understanding the nature of 
cross-reactivity of 25(OH)D immunoassay, which was driven by concentrations of both 25(OH)D 
and 24R,25(OH)2D3, not of 24R,25(OH)2D3 alone.  Accurate simultaneous measurement of 
multiple vitamin D metabolites using LC-MS/MS may not only aid to our understanding of 
vitamin D biology but also could assist in reducing or correcting for cross-reactivity in 
immunoassays across the full range of concentrations observed in human serum. 
 
Acknowledgements 
Research was supported by funding from the European Union (FP7/2007-2013) under grant 
agreement no. 613977 (ODIN). Bio-banked sera were provided by the National Institute of 
Health and Welfare, Helsinki, Finland as part of ODIN. 
 
References 
[1] M.F. Holick, Vitamin D status: measurement, interpretation, and clinical application, Ann 
Epidemiol, 19 (2009) 73-78.  
[2] C.T. Sempos, R.A. Durazo-Arvizu, N. Binkley, J. Jones, J.M. Merkel, G.D. Carter, 
Developing vitamin D dietary guidelines and the lack of 25-hydroxyvitamin D assay 
standardization: The ever-present past, J Steroid Biochem Mol Biol, 164 (2016) 115-119.  
[3] S.S. Tai, M. Bedner, K.W. Phinney, Development of a Candidate Reference Measurement 
Procedure for the Determination of 25-Hydroxyvitamin D3 and 25-Hydroxyvitamin D2 in Human 
Serum Using Isotope-Dilution Liquid Chromatography-Tandem Mass Spectrometry, Anal Chem, 
82 (2010) 1942-1948. 
[4] M. Bedner, K.A. Lippa, S.S. Tai, An assessment of 25-hydroxyvitamin D measurements in 
comparability studies conducted by the Vitamin D Metabolites Quality Assurance Program, Clin 
Chim Acta, 426 (2013) 6-11. 
[5] H.C. Stepman, A. Vanderroost, K. Van Uytfanghe, L.M. Thienpont, Candidate reference 
measurement procedures for serum 25-hydroxyvitamin D3 and 25-hydroxyvitamin D2 by using 
isotope-dilution liquid chromatography-tandem mass spectrometry, Clin Chem, 57 (2011) 441-
448. 
[6] E.M. Mineva, R.L. Schleicher, M. Chaudhary-Webb, K.L. Maw, J.C. Botelho, H.W. Vesper, 
C.M. Pfeiffer, A candidate reference measurement procedure for quantifying serum 
16 
 
concentrations of 25-hydroxyvitamin D3 and 25-hydroxyvitamin D2 using isotope-dilution liquid 
chromatography-tandem mass spectrometry, Analytical and Bioanalytical Chemistry, 407 (2015) 
5615-5624. 
[7] W.D. Fraser, A.M. Milan, Vitamin D assays: past and present debates, difficulties, and 
developments, Calcif Tissue Int, 92 (2013) 118-127. 
[8] D. Bailey, K. Veljkovic, M. Yazdanpanah, K. Adeli, Analytical measurement and clinical 
relevance of vitamin D(3) C3-epimer, Clin Biochem, 46 (2013) 190-196. 
[9] J.M. van den Ouweland, A.M. Beijers, H. van Daal, Overestimation of 25-hydroxyvitamin D3 
by increased ionisation efficiency of 3-epi-25-hydroxyvitamin D3 in LC-MS/MS methods not 
separating both metabolites as determined by an LC-MS/MS method for separate quantification 
of 25-hydroxyvitamin D3, 3-epi-25-hydroxyvitamin D3 and 25-hydroxyvitamin D2 in human 
serum, J Chromatogr B, 967 (2014) 195-202. 
[10] K.D. Cashman, A. Hayes, K. Galvin, J. Merkel, G. Jones, M. Kaufmann, A.N. Hoofnagle, 
G.D. Carter, R.A. Durazo-Arvizu, C.T. Sempos, Significance of serum 24,25-dihydroxyvitamin D 
in the assessment of vitamin D status: a double-edged sword?, Clin Chem, 61 (2015) 636-645. 
[11] M. Kaufmann, J.C. Gallagher, M. Peacock, K.P. Schlingmann, M. Konrad, H.F. DeLuca, R. 
Sigueiro, B. Lopez, A. Mourino, M. Maestro, R. St-Arnaud, J.S. Finkelstein, D.P. Cooper, G. 
Jones, Clinical utility of simultaneous quantitation of 25-hydroxyvitamin D and 24,25-
dihydroxyvitamin D by LC-MS/MS involving derivatization with DMEQ-TAD, J Clin Endocrinol 
Metab, 99 (2014) 2567-2574. 
[12] A.H. Berg, C.E. Powe, M.K. Evans, J. Wenger, G. Ortiz, A.B. Zonderman, P. 
Suntharalingam, K. Lucchesi, N.R. Powe, S.A. Karumanchi, R.I. Thadhani, 24,25-
dihydroxyvitamin D3 and vitamin D status of community-dwelling black and white Americans, 
Clin Chem, 61 (2015) 877-884. 
[13] G.D. Carter, J.C. Jones, J. Shannon, E.L. Williams, G. Jones, M. Kaufmann, C. Sempos, 
25-Hydroxyvitamin D assays: Potential interference from other circulating vitamin D metabolites, 
J Steroid Biochem Mol Biol, 164 (2016) 134-138.  
[14] K.D. Cashman, K.G. Dowling, Z. Škrabáková, M. Kiely, C. Lamberg-Allardt, R.A. Durazo-
Arvizu, C.T. Sempos, S. Koskinen, A. Lundqvist, J. Sundvall, A. Linneberg, B. Thuesen, L.L.N. 
Husemoen, H.E. Meyer, K. Holvik, I.M. Grønborg, I. Tetens, R. Andersen, Standardizing serum 
25-hydroxyvitamin D data from four Nordic population samples using the Vitamin D 
Standardization Programprotocols: Shedding new light on vitamin D status in Nordic individuals, 
Scand J Clin Lab Investig, 75 (2015) 549-561. 
[15] K.D. Cashman, K.G. Dowling, Z. Skrabakova, M. Gonzalez-Gross, J. Valtuena, S. De 
Henauw, L. Moreno, C.T. Damsgaard, K.F. Michaelsen, C. Molgaard, R. Jorde, G. Grimnes, G. 
Moschonis, C. Mavrogianni, Y. Manios, M. Thamm, G.B.M. Mensink, M. Rabenberg, M.A. 
Busch, L. Cox, S. Meadows, G. Goldberg, A. Prentice, J.M. Dekker, G. Nijpels, S. Pilz, K.M. 
Swart, N.M. van Schoor, P. Lips, G. Eiriksdottir, V. Gudnason, M.F. Cotch, S. Koskinen, C. 
Lamberg-Allardt, R.A. Durazo-Arvizu, C.T. Sempos, M. Kiely, Vitamin D deficiency in Europe: 
pandemic?, Am J Clin Nutr, 103 (2016) 1033-1044. 
[16] M.J. Muller, D.A. Volmer, Mass spectrometric profiling of vitamin D metabolites beyond 25-
hydroxyvitamin D, Clin Chem, 61 (2015) 1033-1048. 
[17] T. Higashi, K. Shimada, Application of Cookson-type reagents for biomedical HPLC and 
LC/MS analyses: a brief overview, Biomed Chromatogr, (2016) 1-10. DOI 10.1002/bmc.3808  
17 
 
[18] N.S. Abu Kassim, F.P. Gomes, P.N. Shaw, A.K. Hewavitharana, Simultaneous quantitative 
analysis of nine vitamin D compounds in human blood using LC-MS/MS, Bioanalysis, 8 (2016) 
397-411. 
[19] M.J. Müller, C.S. Stokes, F. Lammert, D.A. Volmer, Chemotyping the distribution of vitamin 
D metabolites in human serum, Scientific Reports, 6, 21080 (11 Feb 2016). DOI 
10.1038/srep21080 
[20] M. Satoh, T. Ishige, S. Ogawa, M. Nishimura, K. Matsushita, T. Higashi, F. Nomura, 
Development and validation of the simultaneous measurement of four vitamin D metabolites in 
serum by LC–MS/MS for clinical laboratory applications, Anal Bioanal Chem, 408 (2016) 7617-
7627. 
[21] C. Hanson, G. Jones, E. Lyden, M. Kaufmann, L. Armas, A. Anderson-Berry, Vitamin D 
metabolism in the premature newborn: A randomized trial, Clin Nutr, 35 (2016) 835-841. 
[22] C.J. Hedman, D.A. Wiebe, S. Dey, J. Plath, J.W. Kemnitz, T.E. Ziegler, Development of a 
sensitive LC/MS/MS method for vitamin D metabolites: 1,25 Dihydroxyvitamin D2&3 
measurement using a novel derivatization agent, J Chromatogr B, 953-954 (2014) 62-67. 
[23] A. Mena-Bravo, F. Priego-Capote, M.D. Luque de Castro, Two-dimensional liquid 
chromatography coupled to tandem mass spectrometry for vitamin D metabolite profiling 
including the C3-epimer-25-monohydroxyvitamin D3, J Chromatogr A, 1451 (2016) 50-57. 
[24] S. Baecher, A. Leinenbach, J.A. Wright, S. Pongratz, U. Kobold, R. Thiele, Simultaneous 
quantification of four vitamin D metabolites in human serum using high performance liquid 
chromatography tandem mass spectrometry for vitamin D profiling, Clin Biochem, 45 (2012) 
1491-1496. 
[25] M.W. Clarke, R.C. Tuckey, S. Gorman, B. Holt, P.H. Hart, Optimized 25-hydroxyvitamin D 
analysis using liquid–liquid extraction with 2D separation with LC/MS/MS detection, provides 
superior precision compared to conventional assays, Metabolomics, 9 (2013) 1031-1040. 
[26] C. Jenkinson, A.E. Taylor, Z.K. Hassan-Smith, J.S. Adams, P.M. Stewart, M. Hewison, B.G. 
Keevil, High throughput LC–MS/MS method for the simultaneous analysis of multiple vitamin D 
analytes in serum, J Chromatogr B, 1014 (2016) 56-63. 
[27] K.D. Cashman, M. Kiely, M. Kinsella, R.A. Durazo-Arvizu, L. Tian, Y. Zhang, A. Lucey, A. 
Flynn, M.J. Gibney, H.W. Vesper, K.W. Phinney, P.M. Coates, M.F. Picciano, C.T. Sempos, 
Evaluation of Vitamin D Standardization Program protocols for standardizing serum 25-
hydroxyvitamin D data: a case study of the program's potential for national nutrition and health 
surveys, Am J Clin Nutr, 97 (2013) 1235-1242. 
[28] Institute of Medicine, Dietary Reference Intakes for Calcium and Vitamin D, The National 
Academies Press, Washington, DC, 2011. 
http://www.nationalacademies.org/hmd/Reports/2010/Dietary-Reference-Intakes-for-Calcium-
and-Vitamin-D.aspx 
[29] M.F. Holick, N.C. Binkley, H.A. Bischoff-Ferrari, C.M. Gordon, D.A. Hanley, R.P. Heaney, 
M.H. Murad, C.M. Weaver, Endocrine Society, Evaluation, treatment, and prevention of vitamin 
D deficiency: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab, 96 
(2011) 1911-1930. 
[30] European Medicines Agency, Guideline on bioanalytical method validation, in: Committee 





09686.pdf (accessed 11/09/16) 
[31] Food and Drug Administration, Guidance for Industry: Bioanalytical Method Validation, in: 
U.S.D.f. Health, and Human Services, Center for Drug Evaluation and Research, Rockville, MD 
USA, 2001. http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf (accessed 
11/09/16) 
[32] J.M. El-Khoury, E.Z. Reineks, S. Wang, Progress of liquid chromatography-mass 
spectrometry in measurement of vitamin D metabolites and analogues, Clin Biochem, 44 (2014) 
66-76. 
[33] A.J. Brown, E. Statopolsky, Vitamin D analogs: Therapeutic applications and mechanisms 
for selectivity, Molecular Aspects of Medicine, 29 (2008) 433-452. 
[34] National Institute of Standards and Technology, Certificate of Analysis Standard Reference 
Material 972a, in: Department of Commerce, Gaithersburg, MD 20899, 15 Sept 2015. 
https://www-s.nist.gov/srmors/certificates/972A.pdf (accessed 1/30/17) 
[35] S.A. Wise, S.S.C. Tai, M.A. Nelson, C.Q. Burdette, J.E. Camara, A.N. Hoofnagle, T.J. Laha, 
G.D. Carter, J. Jones, E.L. Williams, Z. Barclay, G. Jones, M. Kaufmann, N. Binkley, A. Kapoor, 
T. Ziegler, K.D. Cashman, K.G. Dowling, P.M. Coates, C.T. Sempos.  Interlaboratory comparison 
for the determination of 24,25-dihydroxyvitamin D3 in human serum using liquid chromatography-
tandem mass spectrometry.  The Journal of AOAC International (in revision). 
[36] Terveyden ja Hyvinvoinnin Laitos (National Institute for Health and Welfare Finland), The 
Migrant Health and Wellbeing Survey (Maamu) Results, 
http://www.slideshare.net/THLfi/migrant-health-andwellbeingsurveymaamu, 25 Feb 2014. 
[37] Cashman KD, Kiely M. Towards prevention of vitamin D deficiency  and beyond - knowledge 
gaps and research needs in vitamin D nutrition and public health. Br J Nutr 2011;106:1617–27. 







Figure 1: Structures and molecular weights of 4 vitamin D metabolites 
 
Figure 2: MRM chromatograms of A) native serum with 15 nmol/L 24R,25(OH)2D3 and unknown 
interferent peak (arrow); B) serum spiked with 15 nmol/L 24R,25(OH)2D3; C) new gradient 
separating interferent (arrow). 
 
Figure 3: Combined MRM chromatograms with retention times of 24R,25(OH)2D3, 25(OH)D3, 3-
epi-25(OH)D3, and 25(OH)D2 standards. 25(OH)D3 and 3-epi-25(OH)D3 are isobaric and have 




Figure 4: Comparison of sera with total 25(OH)D measured by Architect Chemiluminescent 
Microparticle Immuno Assay (CMIA) [unadjusted () and adjusted for 24R,25(OH)2D3 (▲)] vs. 
LC-MS/MS. CMIA measurements were adjusted according to the equation [Adjusted CMIA] = 







Table 1: Conditions of Triple Quadrupole MS  
Source (ES+) parameters     Compound  Transition*  Cone (V) Collision (eV) 
Capillary (kV)   3.2    24R,25(OH)2D3  417.3 → 121.0 





Extractor (V)   2    d6-24R,25(OH)2D3  423.3 → 121.1 22 20 
RF lens (V)   0.5    25(OH)D3**  401.3 → 159.0 





Source Temp (°C)   120   d6-25(OH)D3  407.4 → 159.1 20 25 
Desolvation Temp (°C)   450   d3-3epi-25(OH)D3  404.4 → 162.0 21 27 
Desolvation gas flow (L/hr)   900   25(OH)D2  413.3 → 355.3 





Cone gas flow (L/hr)   30    [13C]3-25(OH)D2  416.2 → 355.2 17 14 
Collision gas flow (mL/min)   0.12     All dwell times 
= 0.2 s 
  
*quantifier is listed first 
**includes 3-epi-25(OH)D3  
 
Table 2: Target concentrations of vitamin D metabolites (nmol/L) in National Institute of Standards and 
Technology Reference Serum SRM 927a [34]. Concentrations marked with * are certified values, all 
others are reference values. †Sample spiked with exogenous 3-epi-25(OH)D3 
Vitamin D metabolite Level 1 Level 2 Level 3 Level 4 
24R,25(OH)2D3 6.38 + 0.23 3.39 + 0.12 3.88 + 0.13 6.32 + 0.22 
25(OH)D3 *71.7 + 2.7 *45.1 + 1.0 *49.5 + 1.1 *73.4 + 2.3 
3-epi-25(OH)D3 *4.5 + 0.2 *3.2 + 0.2 2.9 + 0.4 *†64.8 + 5.4 
25(OH)D2 1.3 + 0.2 *2.0 + 0.2 *32.3 + 0.8 1.3 + 0.2 
 























    I 1.7 13.5 3.7 
24R,25(OH)2D3 0.65 1.15-73.4 55 (5) II 4.1 9.2 8.0 
    III 9.0 5.2 9.9 
    I 28.4 2.6 4.6 
25(OH)D3 0.31 2.52-323 83 (6) II 55.6 2.2 8.3 
    III 87.3 2.8 6.3 
    I <1.35 - - 
3-epi-25(OH)D3 0.17 1.35-86.6 81 (7) II 1.7 14.3 11.4 
    III 3.6 11.0 9.8 
    I 3.4 10.2 4.0 
25(OH)D2 0.12 2.19-140 86 (8) II 4.4 6.7 3.0 
    III <2.19 - - 





Table 4: Serum concentrations of four vitamin D metabolites and selected metabolite ratios from 
the full subsample (n=156) of Finnish Migrant Health and Wellbeing Study (Maamu) 
participants, and stratified into 3 subgroups based on low, medium and high serum 25(OH)D3 
concentration (<30, 30-75 and >75 nmol/L). 
  Vitamin D analyte (nmol/L) 










sera* Mean 42.6 1.7 3.7 0.073 1.5 0.025 
Full set SD 28.7 1.5 4.0 0.029 2.2 0.022 
n=156 Range 4.8-134 <0.1-16.4 <0.7-20.5 0.023-0.19 <0.2-12.6 0.002-0.13 




Mean 19.0 1.4 1.1 0.057 0.3 0.02 
SD 6.8 0.7 0.6 0.020 0.3 0.02 
Range 4.8-29.4 <0.1-4.0 <0.7-2.6 0.023-0.12 <0.2-1.3 0.004-0.06 
Controls† Spiked control A*  27.5 3.7 25.4 0.894 1.4 0.049 
  Pooled control I** 27.1 3.7 2.2 0.060 1.0 0.048 




Mean 44.8 2.0 3.4 0.074 1.02 0.022 
SD 10.1 2 1.5 0.020 0.69 0.013 
Range 29.5-70.5 0.6-16.4 1.5-9.5 0.041-0.14 <0.2-4.2 0.002-0.066 
Controls† Spiked control B**  36.8 42.3 3.2 0.087 1.7 0.046 
 Spiked control C* 42.2 41.9 3.2 0.076 42.3 1.00 
 Pooled control II** 57.6 4.5 4.1 0.071 1.8 0.031 




Mean 102 1.1 12.0 0.12 6.1 0.060 
SD 14 0.7 3.8 0.028 2.7 0.028 
Range 76.6-134 <0.1-3.0 6.7-20.5 0.076-0.19 0.4-12.6 0.005-0.13 
Controls† Spiked control D** 85.2 82.7 3.3 0.039 1.5 0.018 
 Spiked control E* 97.2 87.7 2.8 0.029 68.0 0.70 
  Pooled control III** 83.6 2.0 9.4 0.11 3.4 0.041 
*Serum measured singly   
**Serum measured in duplicate 
†For description of control samples, see Section 2.2   
 
 
 
